Dutch MEB position on prescription of biosimilar medicinal products
The Netherlands’ Medicines Evaluation Board (MEB) has updated its position about biosimilar medicinal products, saying that biosimilars have been proven to have no relevant differences compared to an innovator biological medicinal product as far as quality, safety and efficacy are concerned.
The MEB adopted a position about biosimilars in 2010. At the time, the agency was of the opinion that patients must be kept on a biological medicinal product as much as possible if they respond well to it clinically.
Based on a careful study of the most recent literature and experiences in the evaluation of biosimilars, the MEB deems that this strict condition is no longer valid. There is enough evidence to support the use of biosimilars in clinical practice, provided this occurs with caution and under certain conditions. However, these conditions are essential.
Conditions for permitting biosimilar products
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze